Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications

Clinical Biochemistry

Volumn 49, Issue 12, 2016, Pages 862-867

  Zsíros, Noémi ^a   Koncsos, Péter ^a   Lőrincz, Hajnalka ^a   Seres, Ildikó ^a   Katkó, Mónika ^a   Szentpéteri, Anita ^a   Varga, Viktória E ^a   Fülöp, Péter ^a   Paragh, György ^a   Harangi, Mariann ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Hyperlipidemia; MMP 9; Myeloperoxidase; Obesity; Paraoxonase 1; TIMP 1

Indexed keywords

ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; GELATINASE B; MYELOPEROXIDASE; PARAOXONASE 1 ARYLESTERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; MMP9 PROTEIN, HUMAN; PEROXIDASE; PON1 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SPECTROPHOTOMETRY; AGED; ATHEROSCLEROSIS; BLOOD; COMPLICATION; FOLLOW UP; MIDDLE AGED; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OBESITY; OVERWEIGHT; OXIDATIVE STRESS; PEROXIDASE; PROGNOSIS; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84965151887     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.03.011     Document Type: Article

References (37)

1. [1] Haslam, D.W., James, W.P., Obesity. Lancet 366 (2005), 1197–1209.
2. [2] Nakamura, K., Fuster, J.J., Walsh, K., Adipokines: a link between obesity and cardiovascular disease. J. Cardiol. 63 (2014), 250–259.
3. [3] Nicholls, S.J., Hazen, S.L., Myeloperoxidase, modified lipoproteins, and atherogenesis. J. Lipid Res. 50 (2009), S346–S351.
4. [4] Moldoveanu, E., Tanaseanu, C., Tanaseanu, S., Kosaka, T., Manea, G., Marta, D.S., et al. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur. J. Intern. Med. 17 (2006), 38–42.
5. [5] Huang, Y., Wu, Z., Riwanto, M., Gao, S., Levison, B.S., Gu, X., et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest. 123 (2013), 3815–3828.
6. [6] Undurti, A., Huang, Y., Lupica, J.A., Smith, J.D., DiDonato, J.A., Hazen, S.L., Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 284 (2009), 30825–30835.
7. [7] Zheng, L., Nukuna, B., Brennan, M.L., Sun, M., Goormastic, M., Settle, M., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114 (2004), 529–541.
8. [8] Kataoka, Y., Shao, M., Wolski, K., Uno, K., Puri, R., Murat Tuzcu, E., et al. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound. Atherosclerosis 232 (2014), 377–383.
9. [9] Gugliucci, A., Menini, T., Paraoxonase 1 and HDL maturation. Clin. Chim. Acta 439 (2015), 5–13.
10. [10] Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M., et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 107 (2003), 2775–2779.
11. [11] Paragh, G., Seres, I., Balogh, Z., Varga, Z., Karpati, I., Matyus, J., et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80 (1998), 166–170.
12. [12] Ferretti, G., Bacchetti, T., Moroni, C., Savino, S., Liuzzi, A., Balzola, F., et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J. Clin. Endocrinol. Metab. 90 (2005), 1728–1733.
13. [13] Roest, M., van Himbergen, T.M., Barendrecht, A.B., Peeters, P.H., van der Schouw, Y.T., Voorbij, H.A., Genetic and environmental determinants of the PON-1 phenotype. Eur. J. Clin. Investig. 37 (2007), 187–196.
14. [14] Jornayvaz, F.R., Brulhart-Meynet, M.C., James, R.W., Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr. Metab. Cardiovasc. Dis. 19 (2009), 613–619.
15. [15] Nagase, H., Visse, R., Murphy, G., Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69 (2006), 562–573.
16. [16] Mittal, B., Mishra, A., Srivastava, A., Kumar, S., Garg, N., Matrix metalloproteinases in coronary artery disease. Adv. Clin. Chem. 64 (2014), 1–72.
17. [17] Sini, S., Deepa, D., Harikrishnan, S., Jayakumari, N., Evidence for an exclusive association of matrix metalloproteinase-9 with dysfunctional high-density lipoprotein: a novel finding. Atherosclerosis 236 (2014), 162–168.
18. [18] Wang, W., Song, X., Chen, Y., Yuan, F., Xu, F., Zhang, M., et al. The long-term influence of tissue inhibitor of matrix metalloproteinase-1 in patients with mild to moderate coronary artery lesions in a Chinese population: a 7-year follow-up study. Cardiology 132 (2015), 151–158.
19. [19] Inokubo, Y., Hanada, H., Ishizaka, H., Fukushi, T., Kamada, T., Okumura, K., Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 141 (2001), 211–217.
20. [20] Cavusoglu, E., Ruwende, C., Chopra, V., Yanamadala, S., Eng, C., Clark, L.T., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am. Heart. J., 151, 2006 (1101.e1–8).
21. [21] Kelly, D., Squire, I.B., Khan, S.Q., Dhillon, O., Narayan, H., Ng, K.H., Quinn, P., et al. Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction. Am. J. Cardiol. 106 (2010), 477–482, 10.1016/j.amjcard.2010.03.060.
22. [22] Andreou, I., Tousoulis, D., Miliou, A., Tentolouris, C., Zisimos, K., Gounari, P., et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 210 (2010), 194–198.
23. [23] Andrade, V.L., do Valle, I.B., Sandrim, V.C., Simvastatin therapy decreases MMP-9 levels in obese women. J. Clin. Pharmacol. 53 (2013), 1072–1077.
24. [24] Harangi, M., Mirdamadi, H.Z., Seres, I., Sztanek, F., Molnár, M., Kassai, A., et al. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl. Res. 153 (2009), 190–198.
25. [25] Kosmala, W., Plaksej, R., Przewlocka-Kosmala, M., Kuliczkowska-Plaksej, J., Bednarek-Tupikowska, G., Mazurek, W., Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int. J. Obes. 32 (2008), 763–771.
26. [26] Tumova, E., Sun, W., Jones, P.H., Vrablik, M., Ballantyne, C.M., Hoogeveen, R.C., The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J. Obes., 2013, 2013, 729515.
27. [27] Fülöp, P., Seres, I., Lőrincz, H., Harangi, M., Somodi, S., Paragh, G., Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J. Cell. Mol. Med. 18 (2014), 1313–1320.
28. [28] Paragh, G., Asztalos, L., Seres, I., Balogh, Z., Löcsey, L., Kárpáti, I., et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 83 (1999), 126–131.
29. [29] Eckerson, H.W., Wyte, C.M., La Du, B.N., The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983), 1126–1138.
30. [30] Smolen, A., Eckerson, H.W., Gan, K.N., Hailat, N., La Du, B.N., Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19 (1991), 107–112.
31. [31] Galis, Z.S., Sukhova, G.K., Lark, M.W., Libby, P., Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94 (1994), 2493–2503.
32. [32] Yunoki, K., Naruko, T., Inaba, M., Inoue, T., Nakagawa, M., Sugioka, K., et al. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. Atherosclerosis 231 (2013), 308–314.
33. [33] Haraguchi, Y., Toh, R., Hasokawa, M., Nakajima, H., Honjo, T., Otsui, K., et al. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis 234 (2014), 288–294.
34. [34] Jucaite, A., Svenningsson, P., Rinne, J.O., Cselényi, Z., Varnäs, K., Johnström, P., et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain 138 (2015), 2687–2700, 10.1093/brain/awv184.
35. [35] Zhang, H., Jing, X., Shi, Y., Xu, H., Du, J., Guan, T., et al. N-acetyl lysyltyrosylcysteine amide inhibits myeloperoxidase, a novel tripeptide inhibitor. J. Lipid Res. 54 (2013), 3016–3029, 10.1194/jlr.M038273.
36. [36] Ruggeri, R.B., Buckbinder, L., Bagley, S.W., Carpino, P.A., Conn, E.L., Dowling, M.S., et al. Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): a highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases. J. Med. Chem. 58 (2015), 8513–8528, 10.1021/acs.jmedchem.5b00963.
37. [37] Zheng, W., Warner, R., Ruggeri, R., Su, C., Cortes, C., Skoura, A., et al. PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. J. Pharmacol. Exp. Ther. 353 (2015), 288–298, 10.1124/jpet.114.221788.